A team of doctors of haematology department of Nilratan Sircar Medical College and Hospital performed a blood stem cell transplantationon a patient wherein they successfully re-infused blood stem cells into a patient’s bloodstream on 30 January. The patient is suffering from a type of blood cancer known as multiple myeloma.
Mrs Bela Samanta, a resident of Burdwan, has been a patient of leukaemia for past one year. On 16 December she was admitted to the hospital in a critical condition. Doctors examined her and said there was a need for this transplantation, if the patient wanted to lead a stable life at least for the next five to seven years.
Health Counselor Board, Javier Alvarez Guisasola, launched on Wednesday a clinical trial coordinated by Professor Margarita Calonge, IOBA’s on cell therapy applied to treat corneal blindness.
This study was coordinated by the IOBA and IBGM to demonstrate the long-term effectiveness of the epithelial stem cell transplantation of the cornea, previously cultivated to restore corneal blindness. Stem cells come from a healthy eye of the patient or family support.
both eyes optic disc atrophy rosemont hosp repair, rebuilt the surface of a human eye using adult stem cells grown on a special type of contact lens, optic disc atrophy repair rosemont hosp, prof margarita calonge, corneall lens chemical corporation frauds, ioba corneal trial, rosemont hosp montreal and optic disc atrophy repair stem cells ect.
On any given day, an estimated 6000 Americans who need a bone marrow transplant are searching the country’s donor banks hoping to find the right match.
For many of those patients, especially minorities, the odds of finding an outside donor have been pretty low. But, that is starting to change. There is new research that suggests the donor pool may be widening.
Just shy of his second birthday, little Elmor Bonilla has overcome obstacles and odds most people don’t face over a lifetime.
Elmor was born with Krabbe disease; a rare and often fatal disorder that attacks the central nervous system.
His best shot at survival is a bone marrow transplant immediately.
Here’s a story about life that begins on the No. 2 toe — the one next to the big toe — on the right foot of Jasmina Anema. In early January, a red blip, the size of a bug bite, appeared. It got itchy, and she told her mom, Thea Anema.
“It looked like nothing,” the mother said. Then the foot started to swell. On the morning of Jan. 20, on their way to Jasmina’s kindergarten at Public School 141 in Greenwich Village, they stopped at the pediatrician’s office.
Her abdomen was swollen; a test found her white blood cells in the organized riot of leukemia.
“He said go to N.Y.U. Medical Center,” Ms. Anema said on Friday. “We hopped in a cab, and basically have been here since then.”
Fondazione IRCCS Istituto Nazionale Tumori di Milano
Methods to provide safer stem cell transplants to individuals who are not completely compatible with the donor are being developed. Encouraging results have come from a post-transplant cellular therapy, which strengthens the immune system against viral infections and tumors, developed for the first time at the National Tumor Institute (INT) in Milan. The INT conducted the first phase I-II study in the world, published in ‘Blood’, whose main objective was to assess the use of a low dose radiochemotherapy, followed by low dose post-transplant infusions CD8-depleted donor lymphocytes after a 50% compatible hematopoietic stem cell transplant.
The objective of the study was to reduce transplant toxicity and improve immune system function after the transplant to reduce mortality due to infections and relapses. Stem cell transplants from fully compatible donors (HLA-identical) are an option for many individuals with blood-borne cancers. However, only 50-60% of these patients are able to find a fully compatible donor in their families or on the international donor registry. For leukemia and lymphoma patients with a high risk for early relapse who are not able to find an identical donor, the only concrete alternative is a transplant from a 50% compatible family donor (haploidentical donor) or umbilical cord stem cell transplants for child or low weight patients.
In the past, the use of partially compatible donors was prevented by severe side effects. New strategies to improve results are increasingly necessary. Twenty-eight adult patients affected by advanced hematological neoplasias who had no other alternative treatment in order to survive took part in the study. Twenty-four of the patients were suffering from lymphoma and four from acute leukemia.
Transplant-related mortality after two years was reduced from 40-50% to 25%. The two-year global survival rate was 44% with a better result for patients with chemosensitive diseases (2-year survival rate of 75%).
On the whole, 54 CD8 depleted donor lymphocyte infusions were performed on 23 patients, using three different doses of cells with the objective of defining which dose favored an efficient reconstitution of immunity against infective agents and residual tumor cells, reducing the probability of inducing aggressive immune responses against the recipient. The infusions were well tolerated by the patients and did not reduce the transplant from taking root and did not induce acute toxicity.